SequelSEC

ADC Therapeutics SA ADCT

Pharmaceutical Preparations · CIK 0001771910 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$79.58M
Fiscal year ended 2026-06-30
Operating income
-$99.55M
Fiscal year ended 2026-06-30
Free cash flow
-$102.30M
Fiscal year ended 2026-06-30

Valuation, from the filing

Public float$136.40MMarket value of stock held by non-affiliates, as stated on the cover page for 2025-06-30
Float per share$1.07Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself.
Float / revenue1.7×A lower bound on the multiple, because affiliate holdings are excluded.

Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-06-30, not today, and each multiple below it uses the figures for the fiscal year ending 2025-12-31 — the year that filing covered.

How this compares in its industry

Percentile among the Pharmaceutical Preparations filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.

MeasureReportedPercentile
Gross margin92.9%89th
CapEx / revenue0.3%22th
SBC / revenue8.5%32th
Revenue YoY growth14.9%62th
FCF margin-173.8%42th
Current ratio4.37x56th
R&D / revenue127.8%46th
Operating margin-149.3%54th
Net margin-175.3%49th

ADC Therapeutics SA (ADCT) reported revenue of $79.58M and net income of -$96.91M for the fiscal year ended 2026-06-30. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from ADC Therapeutics SA’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

ADC Therapeutics SA income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Revenue$79.58M
Cost of revenueUnavailable
Gross profitUnavailable
Operating income-$99.55M
Net income-$96.91M
Research & development$82.23M
Weighted-average diluted sharesUnavailable
Pretax income-$97.31M
Income tax expense-$404.00K
Diluted EPSUnavailable
Selling, general & administrative$85.33M
General & administrative$37.38M
Selling & marketing$47.95M

Balance

ADC Therapeutics SA balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Cash & equivalents$219.11M
Total assets$279.38M
Current assets$261.71M
Total liabilities$507.58M
Current liabilities$86.33M
Total equity incl. NCI-$228.20M
Temporary (mezzanine) equityUnavailable
Inventory$4.93M
Accounts receivableUnavailable
GoodwillUnavailable
Long-term debtUnavailable
Accounts payable$12.76M

Cash flow

ADC Therapeutics SA cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Operating cash flow-$102.27M
Capital expenditures$32.00K
Investing cash flow$627.00K
Financing cash flow$56.21M
Net change in cashUnavailable
Stock-based compensation$9.66M
Common dividends paidUnavailable
Common share repurchasesUnavailable
Depreciation & amortizationUnavailable

Derived

ADC Therapeutics SA derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Free cash flow-$102.30M
Gross marginUnavailable
Operating margin-125.1%
FCF margin-128.5%
SBC / revenue12.1%
Current ratio3.03x
Revenue YoY growth3.0%
Net margin-121.8%
R&D / revenue103.3%
CapEx / revenue0.0%
Long-term debt / equityUnavailable
Effective tax rateUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open ADCT in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-13View SEC filing
10-Q · Filed 2026-05-04View SEC filing
10-K · Filed 2026-03-10View SEC filing
10-Q · Filed 2025-11-10View SEC filing
10-Q · Filed 2025-08-12View SEC filing
10-Q · Filed 2025-05-14View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.